# Study of Efficacy of CDZ173 in Patients With APDS/PASLI

> **NCT02435173** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 37 (actual)

## Conditions studied

- Common Variable Immunodeficiency (CVID), APDS / PASLI

## Interventions

- **DRUG:** CDZ173
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02435173
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-24
- **Primary completion:** 2021-08-16
- **Final completion:** 2021-08-16
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2022-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02435173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02435173, "Study of Efficacy of CDZ173 in Patients With APDS/PASLI". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02435173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*